Search
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia
Boehringer Ingelheim is driving localization capacities with robust partnerships in alignment with Vision 2030
Obesity
Obesity
Empowering and Upskilling Patient Organizations in the IMETA Region
Boehringer Ingelheim held the first PULSE training programme in Dubai, bringing together over twenty representatives of patient organizations from across India, the Middle East, Turkey, and Africa.
Illuminating Connections, Inspiring Hope
Illuminating Connections, Inspiring Hope is a public awareness and engagement initiative launched by Boehringer Ingelheim in collaboration with the Dubai Health Authority. It aims to raise awareness of the interconnectivity between cardiovascular, renal,
Introducing Karl and Klara Kidney
Kidney disease and type 2 diabetes are closely linked, and share many of the same risk factors and pathological pathways
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
Immuno-Oncology
We are unlocking the broader possibilities of immuno-oncology, taking cancer on through the power of the body’s immune system.
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
Patient documentary - From diagnosis to everyday living
Patient documentary - From diagnosis to everyday living
World Heart Day 2021
Cardiovascular diseases, including heart disease, are the leading cause of death and disability worldwide and are closely linked to kidney and metabolic diseases.
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
In 2023, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increase compared to the previous year.
Industry 40 Innovation in France
Our sites in the Lyon area and Toulouse are investing in the industry of the future.
REACH / GHS / Material safety data sheets
We are continuously working on these topics with the aim to be in compliance with requirements deriving from these legislations.
Cardiovascular Disease
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
NASH
NASH
Collaboration Driving Innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.